Neurotrophic Keratitis Market - Global Outlook and Forecast 2022-2028

March 2022 | 67 pages | ID: N32A3194D7CFEN
Market Monitor Global

Abstracts

Neurotrophic keratitis (NK) is a degenerative disease of the cornea caused by damage of the trigeminal nerve, which results in impairment of corneal sensitivity, spontaneous corneal epithelium breakdown, poor corneal healing and development of corneal ulceration, melting and perforation.

This report contains market size and forecasts of Neurotrophic Keratitis in Global, including the following market information:

Global Neurotrophic Keratitis Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Neurotrophic Keratitis market was valued at 105.5 million in 2021 and is projected to reach US$ 289.3 million by 2028, at a CAGR of 15.5% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Neurotrophic Keratitis include Dompe farmaceutici S.p.A.,, Allergan,, ReGenTree, LLC, Alcon,, Bausch & Lomb Incorporated (Bausch Health Companies Inc.),, CONTACARE,, OHTO Pharmaceutical Co., Ltd.,, Pfizer, Inc.,, Neuroptika and Santen Pharmaceutical Co., Ltd.,, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neurotrophic Keratitis companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Neurotrophic Keratitis Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Neurotrophic Keratitis Market Segment Percentages, by Type, 2021 (%)

• Drugs
• Surgical Intervention

Global Neurotrophic Keratitis Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Neurotrophic Keratitis Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic

Global Neurotrophic Keratitis Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Neurotrophic Keratitis Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Neurotrophic Keratitis revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Neurotrophic Keratitis revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Dompe farmaceutici S.p.A.,
• Allergan,
• ReGenTree, LLC, Alcon,
• Bausch & Lomb Incorporated (Bausch Health Companies Inc.),
• CONTACARE,
• OHTO Pharmaceutical Co., Ltd.,
• Pfizer, Inc.,
• Neuroptika
• Santen Pharmaceutical Co., Ltd.,
• Johnson & Johnson,
• Grand Pharma (China) Co., Ltd., and
• Zhejiang CONBA Pharmaceutical Co., Ltd.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Neurotrophic Keratitis Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Neurotrophic Keratitis Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL NEUROTROPHIC KERATITIS OVERALL MARKET SIZE

2.1 Global Neurotrophic Keratitis Market Size: 2021 VS 2028
2.2 Global Neurotrophic Keratitis Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Neurotrophic Keratitis Players in Global Market
3.2 Top Global Neurotrophic Keratitis Companies Ranked by Revenue
3.3 Global Neurotrophic Keratitis Revenue by Companies
3.4 Top 3 and Top 5 Neurotrophic Keratitis Companies in Global Market, by Revenue in 2021
3.5 Global Companies Neurotrophic Keratitis Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neurotrophic Keratitis Players in Global Market
  3.6.1 List of Global Tier 1 Neurotrophic Keratitis Companies
  3.6.2 List of Global Tier 2 and Tier 3 Neurotrophic Keratitis Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Neurotrophic Keratitis Market Size Markets, 2021 & 2028
  4.1.2 Drugs
  4.1.3 Surgical Intervention
4.2 By Type - Global Neurotrophic Keratitis Revenue & Forecasts
  4.2.1 By Type - Global Neurotrophic Keratitis Revenue, 2017-2022
  4.2.2 By Type - Global Neurotrophic Keratitis Revenue, 2023-2028
  4.2.3 By Type - Global Neurotrophic Keratitis Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Neurotrophic Keratitis Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Clinic
5.2 By Application - Global Neurotrophic Keratitis Revenue & Forecasts
  5.2.1 By Application - Global Neurotrophic Keratitis Revenue, 2017-2022
  5.2.2 By Application - Global Neurotrophic Keratitis Revenue, 2023-2028
  5.2.3 By Application - Global Neurotrophic Keratitis Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Neurotrophic Keratitis Market Size, 2021 & 2028
6.2 By Region - Global Neurotrophic Keratitis Revenue & Forecasts
  6.2.1 By Region - Global Neurotrophic Keratitis Revenue, 2017-2022
  6.2.2 By Region - Global Neurotrophic Keratitis Revenue, 2023-2028
  6.2.3 By Region - Global Neurotrophic Keratitis Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Neurotrophic Keratitis Revenue, 2017-2028
  6.3.2 US Neurotrophic Keratitis Market Size, 2017-2028
  6.3.3 Canada Neurotrophic Keratitis Market Size, 2017-2028
  6.3.4 Mexico Neurotrophic Keratitis Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Neurotrophic Keratitis Revenue, 2017-2028
  6.4.2 Germany Neurotrophic Keratitis Market Size, 2017-2028
  6.4.3 France Neurotrophic Keratitis Market Size, 2017-2028
  6.4.4 U.K. Neurotrophic Keratitis Market Size, 2017-2028
  6.4.5 Italy Neurotrophic Keratitis Market Size, 2017-2028
  6.4.6 Russia Neurotrophic Keratitis Market Size, 2017-2028
  6.4.7 Nordic Countries Neurotrophic Keratitis Market Size, 2017-2028
  6.4.8 Benelux Neurotrophic Keratitis Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Neurotrophic Keratitis Revenue, 2017-2028
  6.5.2 China Neurotrophic Keratitis Market Size, 2017-2028
  6.5.3 Japan Neurotrophic Keratitis Market Size, 2017-2028
  6.5.4 South Korea Neurotrophic Keratitis Market Size, 2017-2028
  6.5.5 Southeast Asia Neurotrophic Keratitis Market Size, 2017-2028
  6.5.6 India Neurotrophic Keratitis Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Neurotrophic Keratitis Revenue, 2017-2028
  6.6.2 Brazil Neurotrophic Keratitis Market Size, 2017-2028
  6.6.3 Argentina Neurotrophic Keratitis Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Neurotrophic Keratitis Revenue, 2017-2028
  6.7.2 Turkey Neurotrophic Keratitis Market Size, 2017-2028
  6.7.3 Israel Neurotrophic Keratitis Market Size, 2017-2028
  6.7.4 Saudi Arabia Neurotrophic Keratitis Market Size, 2017-2028
  6.7.5 UAE Neurotrophic Keratitis Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Dompe farmaceutici S.p.A.,
  7.1.1 Dompe farmaceutici S.p.A., Corporate Summary
  7.1.2 Dompe farmaceutici S.p.A., Business Overview
  7.1.3 Dompe farmaceutici S.p.A., Neurotrophic Keratitis Major Product Offerings
  7.1.4 Dompe farmaceutici S.p.A., Neurotrophic Keratitis Revenue in Global Market (2017-2022)
  7.1.5 Dompe farmaceutici S.p.A., Key News
7.2 Allergan,
  7.2.1 Allergan, Corporate Summary
  7.2.2 Allergan, Business Overview
  7.2.3 Allergan, Neurotrophic Keratitis Major Product Offerings
  7.2.4 Allergan, Neurotrophic Keratitis Revenue in Global Market (2017-2022)
  7.2.5 Allergan, Key News
7.3 ReGenTree, LLC, Alcon,
  7.3.1 ReGenTree, LLC, Alcon, Corporate Summary
  7.3.2 ReGenTree, LLC, Alcon, Business Overview
  7.3.3 ReGenTree, LLC, Alcon, Neurotrophic Keratitis Major Product Offerings
  7.3.4 ReGenTree, LLC, Alcon, Neurotrophic Keratitis Revenue in Global Market (2017-2022)
  7.3.5 ReGenTree, LLC, Alcon, Key News
7.4 Bausch & Lomb Incorporated (Bausch Health Companies Inc.),
  7.4.1 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Corporate Summary
  7.4.2 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Business Overview
  7.4.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Neurotrophic Keratitis Major Product Offerings
  7.4.4 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Neurotrophic Keratitis Revenue in Global Market (2017-2022)
  7.4.5 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Key News
7.5 CONTACARE,
  7.5.1 CONTACARE, Corporate Summary
  7.5.2 CONTACARE, Business Overview
  7.5.3 CONTACARE, Neurotrophic Keratitis Major Product Offerings
  7.5.4 CONTACARE, Neurotrophic Keratitis Revenue in Global Market (2017-2022)
  7.5.5 CONTACARE, Key News
7.6 OHTO Pharmaceutical Co., Ltd.,
  7.6.1 OHTO Pharmaceutical Co., Ltd., Corporate Summary
  7.6.2 OHTO Pharmaceutical Co., Ltd., Business Overview
  7.6.3 OHTO Pharmaceutical Co., Ltd., Neurotrophic Keratitis Major Product Offerings
  7.6.4 OHTO Pharmaceutical Co., Ltd., Neurotrophic Keratitis Revenue in Global Market (2017-2022)
  7.6.5 OHTO Pharmaceutical Co., Ltd., Key News
7.7 Pfizer, Inc.,
  7.7.1 Pfizer, Inc., Corporate Summary
  7.7.2 Pfizer, Inc., Business Overview
  7.7.3 Pfizer, Inc., Neurotrophic Keratitis Major Product Offerings
  7.7.4 Pfizer, Inc., Neurotrophic Keratitis Revenue in Global Market (2017-2022)
  7.7.5 Pfizer, Inc., Key News
7.8 Neuroptika
  7.8.1 Neuroptika Corporate Summary
  7.8.2 Neuroptika Business Overview
  7.8.3 Neuroptika Neurotrophic Keratitis Major Product Offerings
  7.8.4 Neuroptika Neurotrophic Keratitis Revenue in Global Market (2017-2022)
  7.8.5 Neuroptika Key News
7.9 Santen Pharmaceutical Co., Ltd.,
  7.9.1 Santen Pharmaceutical Co., Ltd., Corporate Summary
  7.9.2 Santen Pharmaceutical Co., Ltd., Business Overview
  7.9.3 Santen Pharmaceutical Co., Ltd., Neurotrophic Keratitis Major Product Offerings
  7.9.4 Santen Pharmaceutical Co., Ltd., Neurotrophic Keratitis Revenue in Global Market (2017-2022)
  7.9.5 Santen Pharmaceutical Co., Ltd., Key News
7.10 Johnson & Johnson,
  7.10.1 Johnson & Johnson, Corporate Summary
  7.10.2 Johnson & Johnson, Business Overview
  7.10.3 Johnson & Johnson, Neurotrophic Keratitis Major Product Offerings
  7.10.4 Johnson & Johnson, Neurotrophic Keratitis Revenue in Global Market (2017-2022)
  7.10.5 Johnson & Johnson, Key News
7.11 Grand Pharma (China) Co., Ltd., and
  7.11.1 Grand Pharma (China) Co., Ltd., and Corporate Summary
  7.11.2 Grand Pharma (China) Co., Ltd., and Business Overview
  7.11.3 Grand Pharma (China) Co., Ltd., and Neurotrophic Keratitis Major Product Offerings
  7.11.4 Grand Pharma (China) Co., Ltd., and Neurotrophic Keratitis Revenue in Global Market (2017-2022)
  7.11.5 Grand Pharma (China) Co., Ltd., and Key News
7.12 Zhejiang CONBA Pharmaceutical Co., Ltd.
  7.12.1 Zhejiang CONBA Pharmaceutical Co., Ltd. Corporate Summary
  7.12.2 Zhejiang CONBA Pharmaceutical Co., Ltd. Business Overview
  7.12.3 Zhejiang CONBA Pharmaceutical Co., Ltd. Neurotrophic Keratitis Major Product Offerings
  7.12.4 Zhejiang CONBA Pharmaceutical Co., Ltd. Neurotrophic Keratitis Revenue in Global Market (2017-2022)
  7.12.5 Zhejiang CONBA Pharmaceutical Co., Ltd. Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Neurotrophic Keratitis Market Opportunities & Trends in Global Market
Table 2. Neurotrophic Keratitis Market Drivers in Global Market
Table 3. Neurotrophic Keratitis Market Restraints in Global Market
Table 4. Key Players of Neurotrophic Keratitis in Global Market
Table 5. Top Neurotrophic Keratitis Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Neurotrophic Keratitis Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Neurotrophic Keratitis Revenue Share by Companies, 2017-2022
Table 8. Global Companies Neurotrophic Keratitis Product Type
Table 9. List of Global Tier 1 Neurotrophic Keratitis Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neurotrophic Keratitis Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Neurotrophic Keratitis Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Neurotrophic Keratitis Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Neurotrophic Keratitis Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Neurotrophic Keratitis Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Neurotrophic Keratitis Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Neurotrophic Keratitis Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Neurotrophic Keratitis Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Neurotrophic Keratitis Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Neurotrophic Keratitis Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Neurotrophic Keratitis Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Neurotrophic Keratitis Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Neurotrophic Keratitis Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Neurotrophic Keratitis Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Neurotrophic Keratitis Revenue, (US$, Mn), 2023-2028
Table 30. Dompe farmaceutici S.p.A., Corporate Summary
Table 31. Dompe farmaceutici S.p.A., Neurotrophic Keratitis Product Offerings
Table 32. Dompe farmaceutici S.p.A., Neurotrophic Keratitis Revenue (US$, Mn), (2017-2022)
Table 33. Allergan, Corporate Summary
Table 34. Allergan, Neurotrophic Keratitis Product Offerings
Table 35. Allergan, Neurotrophic Keratitis Revenue (US$, Mn), (2017-2022)
Table 36. ReGenTree, LLC, Alcon, Corporate Summary
Table 37. ReGenTree, LLC, Alcon, Neurotrophic Keratitis Product Offerings
Table 38. ReGenTree, LLC, Alcon, Neurotrophic Keratitis Revenue (US$, Mn), (2017-2022)
Table 39. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Corporate Summary
Table 40. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Neurotrophic Keratitis Product Offerings
Table 41. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Neurotrophic Keratitis Revenue (US$, Mn), (2017-2022)
Table 42. CONTACARE, Corporate Summary
Table 43. CONTACARE, Neurotrophic Keratitis Product Offerings
Table 44. CONTACARE, Neurotrophic Keratitis Revenue (US$, Mn), (2017-2022)
Table 45. OHTO Pharmaceutical Co., Ltd., Corporate Summary
Table 46. OHTO Pharmaceutical Co., Ltd., Neurotrophic Keratitis Product Offerings
Table 47. OHTO Pharmaceutical Co., Ltd., Neurotrophic Keratitis Revenue (US$, Mn), (2017-2022)
Table 48. Pfizer, Inc., Corporate Summary
Table 49. Pfizer, Inc., Neurotrophic Keratitis Product Offerings
Table 50. Pfizer, Inc., Neurotrophic Keratitis Revenue (US$, Mn), (2017-2022)
Table 51. Neuroptika Corporate Summary
Table 52. Neuroptika Neurotrophic Keratitis Product Offerings
Table 53. Neuroptika Neurotrophic Keratitis Revenue (US$, Mn), (2017-2022)
Table 54. Santen Pharmaceutical Co., Ltd., Corporate Summary
Table 55. Santen Pharmaceutical Co., Ltd., Neurotrophic Keratitis Product Offerings
Table 56. Santen Pharmaceutical Co., Ltd., Neurotrophic Keratitis Revenue (US$, Mn), (2017-2022)
Table 57. Johnson & Johnson, Corporate Summary
Table 58. Johnson & Johnson, Neurotrophic Keratitis Product Offerings
Table 59. Johnson & Johnson, Neurotrophic Keratitis Revenue (US$, Mn), (2017-2022)
Table 60. Grand Pharma (China) Co., Ltd., and Corporate Summary
Table 61. Grand Pharma (China) Co., Ltd., and Neurotrophic Keratitis Product Offerings
Table 62. Grand Pharma (China) Co., Ltd., and Neurotrophic Keratitis Revenue (US$, Mn), (2017-2022)
Table 63. Zhejiang CONBA Pharmaceutical Co., Ltd. Corporate Summary
Table 64. Zhejiang CONBA Pharmaceutical Co., Ltd. Neurotrophic Keratitis Product Offerings
Table 65. Zhejiang CONBA Pharmaceutical Co., Ltd. Neurotrophic Keratitis Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Neurotrophic Keratitis Segment by Type in 2021
Figure 2. Neurotrophic Keratitis Segment by Application in 2021
Figure 3. Global Neurotrophic Keratitis Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Neurotrophic Keratitis Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Neurotrophic Keratitis Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Neurotrophic Keratitis Revenue in 2021
Figure 8. By Type - Global Neurotrophic Keratitis Revenue Market Share, 2017-2028
Figure 9. By Application - Global Neurotrophic Keratitis Revenue Market Share, 2017-2028
Figure 10. By Region - Global Neurotrophic Keratitis Revenue Market Share, 2017-2028
Figure 11. By Country - North America Neurotrophic Keratitis Revenue Market Share, 2017-2028
Figure 12. US Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Neurotrophic Keratitis Revenue Market Share, 2017-2028
Figure 16. Germany Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 17. France Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Neurotrophic Keratitis Revenue Market Share, 2017-2028
Figure 24. China Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 28. India Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Neurotrophic Keratitis Revenue Market Share, 2017-2028
Figure 30. Brazil Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Neurotrophic Keratitis Revenue Market Share, 2017-2028
Figure 33. Turkey Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Neurotrophic Keratitis Revenue, (US$, Mn), 2017-2028
Figure 37. Dompe farmaceutici S.p.A., Neurotrophic Keratitis Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Allergan, Neurotrophic Keratitis Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. ReGenTree, LLC, Alcon, Neurotrophic Keratitis Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Neurotrophic Keratitis Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. CONTACARE, Neurotrophic Keratitis Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. OHTO Pharmaceutical Co., Ltd., Neurotrophic Keratitis Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Pfizer, Inc., Neurotrophic Keratitis Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Neuroptika Neurotrophic Keratitis Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Santen Pharmaceutical Co., Ltd., Neurotrophic Keratitis Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Johnson & Johnson, Neurotrophic Keratitis Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Grand Pharma (China) Co., Ltd., and Neurotrophic Keratitis Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Zhejiang CONBA Pharmaceutical Co., Ltd. Neurotrophic Keratitis Revenue Year Over Year Growth (US$, Mn) & (2017-2022)